A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

NCT01638000 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1887

Enrollment

INDUSTRY

Sponsor class

Conditions

Urologic Diseases
Urinary Bladder, Overactive
Urinary Bladder Diseases

Interventions

DRUG: Mirabegron
DRUG: Solifenacin succinate

Sponsor

Astellas Pharma Europe Ltd.